Poziotinib-induced cutaneous adverse reactions in the treatment of non-small cell lung cancer: A case report

Int J Dermatol. 2022 Jun;61(6):769-770. doi: 10.1111/ijd.16205. Epub 2022 Apr 8.

Authors

Haizhen Hui^#^{1

2}, Mengxin Wang^#^{1

2}, Hongxing Guo³, Yingjun Wang^{1

2}, Bingjun Shi¹

Affiliations

¹ Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine (Chongqing Clinical Research Center for Dermatology; Chongqing Key Laboratory of Integrative Dermatology Research), Chongqing, China.
² Guizhou University of Traditional Chinese Medicine, Guiyang, China.
³ Kweichow Moutai Hospital, Renhuai, China.

^# Contributed equally.

PMID: 35394067
DOI: 10.1111/ijd.16205

No abstract available

Keywords: Poziotinib; cutaneous adverse reactions; non-small cell lung cancer.

Publication types

Case Reports
Letter

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy
Protein Kinase Inhibitors / adverse effects
Quinazolines / adverse effects

Substances

HM781-36B
Protein Kinase Inhibitors
Quinazolines